EMR200147-500 - EGRIFTA for abdominal obesity in type 2 diabetes: Retinopathy study

Population: Type 2 diabetes with abdominal obesity
Brief Description: A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA® increases the risk of diabetic retinopathy by formal eye exams when given to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes. 2:1 randomization to EGRIFTA vs placebo. Subject compensation.
Eligibility: Stable ART, physical exam evidence of abdominal obesity, type 2 diabetes, hbg A1C 6-12, stable diabetes med doses or diet controlled, adequate contraception and normal mammogram if >40 years (women), normal prostate exam and PSA (men), no h/o CMV retinitis, no anabolic steroids
Duration: 36 months
Nurse(s): Frances Canchola  323-343-8281
Study Website:




Version en Espanol | English Version

© 2003 - 2009 AIDS Clinical Trials Unit, Keck School of Medicine of USC. All rights reserved.